Frontline Approaches Fine-Tuned in Newly Diagnosed Ovarian Cancer
April 6th 2019Paul Sabbatini, MD, clarifies where the field stands regarding the use of bevacizumab, intraperitoneal therapy, and a 3-week dosing schedule of chemotherapy versus a weekly dose-dense regimen in the frontline setting of newly diagnosed ovarian cancer.
Dr. Leitao on Eligibility for Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
April 2nd 2019Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses patient eligibility for neoadjuvant chemotherapy in advanced ovarian cancer.
Dr. Slovin Discusses Risk Factors for ADT-Associated Cardiac Complications in Prostate Cancer
February 26th 2019Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses risk factors for androgen deprivation therapy (ADT)-associated cardiac complications in prostate cancer.
Dr. Jhaveri Discusses the Potential of Immunotherapy in TNBC
February 22nd 2019Komal Jhaveri, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the potential for immunotherapy in the treatment of patients with triple-negative breast cancer (TNBC) based on results from the IMpassion130 trial.
Dr. Abou-Alfa on the FDA Approval of Cabozantinib in HCC
January 20th 2019Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the FDA approval of cabozantinib (Cabometyx) is likely to shake up the landscape and impact sequencing for patients with hepatocellular carcinoma (HCC).
Dr. Makker on Safety Signals With Lenvatinib and Pembrolizumab in Endometrial Cancer
November 30th 2018Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses safety signals with the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) in endometrial cancer.